<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01222624</url>
  </required_header>
  <id_info>
    <org_study_id>GEXMab25101</org_study_id>
    <nct_id>NCT01222624</nct_id>
  </id_info>
  <brief_title>PankoMab-GEX™: Phase 1 Dose Escalation Study</brief_title>
  <official_title>Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX™ in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glycotope GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glycotope GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open label, dose escalating, multicenter, phase I study measuring the safety,&#xD;
      tolerability, and pharmacokinetics of PankoMab-GEX™ after intravenous administration in&#xD;
      patients with locally advanced or metastatic solid cancers refractory to standard treatment.&#xD;
      The effect of PankoMab-GEX™ on the development of antibodies and tumor response was also&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male or female patients of age 18 years or older with a histologically-confirmed,&#xD;
      tumor-associated mucin 1 (TA-MUC1) positive, measurable or non-measurable solid tumor who had&#xD;
      failed standard therapy and for whom no standard therapy was available.&#xD;
&#xD;
      Open-label, non-randomized, inter-patient dose escalation, multi-center study in a 3 + 3&#xD;
      design.&#xD;
&#xD;
      Patients received PankoMab-GEX™ treatment until disease progression or until the treatment&#xD;
      was no longer tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0</measure>
    <time_frame>Until 28±2 days following the last infusion</time_frame>
    <description>Adverse events coded using Medical Dictionary for Regulatory Activities (MedDRA) version 13.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent abnormal clinical laboratory parameters assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0</measure>
    <time_frame>Until 28±2 days following the last infusion</time_frame>
    <description>Analyzed in local clinical laboratories</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in corrected QT interval (QTc) duration</measure>
    <time_frame>Until 28±2 days following the last infusion</time_frame>
    <description>based on Electrocardiograms (ECG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of left ventricular ejection fraction (LVEF)</measure>
    <time_frame>Until 28±2 days following the last infusion</time_frame>
    <description>based on Multiple Gated Acquisition (MUGA) scan or Echocardiogram (ECHO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Until 28±2 days following the last infusion</time_frame>
    <description>The ECOG Scale of Performance Status describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The scale comprises six grades:&#xD;
0 Fully active, able to carry on all pre-disease performance without restriction&#xD;
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work&#xD;
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours&#xD;
Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours&#xD;
Completely disabled; cannot carry on any selfcare; totally confined to bed or chair&#xD;
Dead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks</time_frame>
    <description>PK of PankoMab-GEX™ in patients after single and multiple dose applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Drug Concentration (Cmin)</measure>
    <time_frame>Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks</time_frame>
    <description>PK of PankoMab-GEX™ in patients after single and multiple dose applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK):Time to reach Cmax (tmax)</measure>
    <time_frame>Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks</time_frame>
    <description>PK of PankoMab-GEX™ in patients after single and multiple dose applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area under the curve (AUC)</measure>
    <time_frame>Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks</time_frame>
    <description>PK of PankoMab-GEX™ in patients after single and multiple dose applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Apparent terminal serum half-life (t1/2)</measure>
    <time_frame>Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks</time_frame>
    <description>PK of PankoMab-GEX™ in patients after single and multiple dose applications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate any immunogenicity</measure>
    <time_frame>Anti-drug antibodies (ADAs) were to be measured before the first infusion of study medication, prior to the second infusion, 4 weeks and 8 weeks after the last study medication administration.</time_frame>
    <description>Anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Best observed response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Tumors were measured by computed tomography (CT)-scan or magnetic resonance imaging (MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Objective response rate (ORR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Tumors were measured by computed tomography (CT)-scan or magnetic resonance imaging (MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Clinical benefit rate (CBR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Tumors were measured by computed tomography (CT)-scan or magnetic resonance imaging (MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Duration of response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Tumors were measured by computed tomography (CT)-scan or magnetic resonance imaging (MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response: Duration of stable disease</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>Tumors were measured by computed tomography (CT)-scan or magnetic resonance imaging (MRI) and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>PankoMab-GEX™, 3-weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application, q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PankoMab-GEX™, 2-weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application q2w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PankoMab-GEX™, weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>application q1w</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PankoMab-GEX™</intervention_name>
    <arm_group_label>PankoMab-GEX™, 2-weekly</arm_group_label>
    <arm_group_label>PankoMab-GEX™, 3-weekly</arm_group_label>
    <arm_group_label>PankoMab-GEX™, weekly</arm_group_label>
    <other_name>gatipotuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female and age ≥ 18 yrs&#xD;
&#xD;
          2. Histologically-confirmed TA-MUC1 positive measurable or non-measurable solid tumors&#xD;
             according to RECIST criteria who failed standard therapy and for whom no further&#xD;
             standard therapy is available (TA-MUC1 positivity assessed by PankoMab-GEX™ staining&#xD;
             in immunohistology of the tumor).&#xD;
&#xD;
          3. Failure of standard therapy or non-availability of standard therapy&#xD;
&#xD;
               -  Patients must have received at least 1 standard chemotherapy during the course of&#xD;
                  the tumor disease&#xD;
&#xD;
               -  All therapies must be completed 6 weeks (therapeutic monoclonal antibodies) or 4&#xD;
                  weeks (all other anti-cancer agents) before start of study treatment and patients&#xD;
                  must have recovered from all prior therapy toxicities to at least CTCAE grade 1&#xD;
&#xD;
          4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1 and estimated life&#xD;
             expectancy of &gt; 3 months&#xD;
&#xD;
          5. Adequate organ function as assessed by the following laboratory parameters within 14&#xD;
             days prior to study drug application:&#xD;
&#xD;
               -  Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x&#xD;
                  10^9/L; absolute neutrophil count (ANC) ≥ 1.5x 10^9/L; platelet count ≥ 100 x&#xD;
                  10^9/L&#xD;
&#xD;
               -  Hepatic: aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤&#xD;
                  2.5 times upper limit of normal (ULN) (≤ 5 x ULN if hepatic metastases present);&#xD;
                  bilirubin ≤ 1.5 x ULN; alkaline phosphatase ≤ 5.0 times upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  Renal: Calculated creatinine clearance &gt; 80 ml/min using the Modification of Diet&#xD;
                  in Renal Disease (MDRD) formula according to Levey 2005: Glomerular filtration&#xD;
                  rate (GFR) (ml/min/1.73 m²) = 186 x (serum creatinine /0,95)^-1.154 x&#xD;
                  (age)^-0.203 x (0.742 females) x (1.21 in black patients)&#xD;
&#xD;
          6. Patients of both genders with procreative potential must use effective contraception&#xD;
             while enrolled in the study and for at least 6 weeks after the last study drug&#xD;
             infusion&#xD;
&#xD;
          7. Written informed consent must be obtained prior to conducting any study-specific&#xD;
             procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Antibody-based immunotherapy within 6 weeks and chemotherapy, radiation or other&#xD;
             anti-cancer therapies within 4 weeks prior to study enrolment&#xD;
&#xD;
          2. Any investigational agents at the study enrolment&#xD;
&#xD;
          3. Concurrent anti-tumor therapy or concurrent immunotherapy&#xD;
&#xD;
          4. Concurrent systemic steroids except topical (inhaled, topical, nasal), replacement&#xD;
             therapy for the last 28 days. Steroids at low and stable dose (up to 20 mg prednisone)&#xD;
             given for chronic disease are also permitted&#xD;
&#xD;
          5. History of allergic reactions to previous antibody therapy&#xD;
&#xD;
          6. Major surgery within 4 weeks prior entering the study and/or incomplete recovery from&#xD;
             surgery or planned major surgery&#xD;
&#xD;
          7. Documented history of active autoimmune disorders requiring systemic immunosuppressive&#xD;
             therapy such as sarcoidosis, lupus erythematosus, rheumatoid arthritis,&#xD;
             glomerulonephritis or systemic vasculitis (except autoimmune thyroiditis with only&#xD;
             thyroid hormone replacement and stable disease &gt;1 year)&#xD;
&#xD;
          8. Primary or secondary immune deficiency&#xD;
&#xD;
          9. Clinically active infections &gt; CTCAE grade 2&#xD;
&#xD;
         10. Prior allergic reaction to a monoclonal antibody (e.g. Trastuzumab, Cetuximab or&#xD;
             Bevacizumab).&#xD;
&#xD;
         11. Active hepatitis B or C; human immunodeficiency virus (HIV) seropositivity&#xD;
&#xD;
         12. Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the&#xD;
             cervix. Patients with a previous malignancy but without evidence of disease for ≥3&#xD;
             years will be allowed to enter the study.&#xD;
&#xD;
         13. Uncontrolled medical condition considered as high risk for the treatment with an&#xD;
             investigational drug including unstable diabetes mellitus, vena-cava-syndrome, chronic&#xD;
             symptomatic respiratory disease.&#xD;
&#xD;
         14. Brain metastasis or leptomeningeal involvement&#xD;
&#xD;
         15. Symptomatic congestive heart failure (New York Heart Association [NYHA] 3 or 4);&#xD;
             unstable angina pectoris within 6 months prior to enrollment; significant cardiac&#xD;
             arrhythmia, history of stroke or transient ischemic attack within 1 year or left&#xD;
             ventricular ejection fraction (LVEF) below the institutional range of normal on a&#xD;
             baseline multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)&#xD;
&#xD;
         16. History of seizures, encephalitis or multiple sclerosis&#xD;
&#xD;
         17. History of deep vein thrombosis and/or thromboembolic events within the past 6 months&#xD;
             before entering the study and/or requiring anticoagulation therapy&#xD;
&#xD;
         18. Evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
         19. Active drug abuse or chronic alcoholism&#xD;
&#xD;
         20. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glycotope GmbH</last_name>
    <role>Study Director</role>
    <affiliation>Glycotope GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glycotope Investigational Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003. Epub 2016 Jun 7.</citation>
    <PMID>27285281</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 15, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid malignancies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

